This person is connected to 6 Board Members in 6 different organizations across 13 different industries.See Board Relationships
1
59
--
Background
Dr. Geoffrey Edward Duncan Brooke, also known as Geoff, M.D., MBBS, MBA, is a Co-Founder and Managing Partner at GBS Venture Partners Limited. Dr. Brooke has more than 20 years of venture capital experience. His experience includes company formation, acquisitions, and public listings. He served as a Managing Director of GBS Venture Partners Limited for six years, when it was a part of the Rothschild Group until November 2002. He served as the Chief Executive Officer of Rothschild Bioscience Unit of Arrow Capital Pty Ltd. Prior to this, he served as the President at Medvest Inc., a company he Co-Founded with Johnson & Johnson. He is the Founder and lead investor of many healthcare and bioscience-based companies in the United States and Australia. He serves as an Executive of private and public companies and has an extensive network of international contacts. He serves as a Non-Executive Director at health.com.au Pty Ltd. and NIA Health Pty Ltd. He serves as a Director of Uptake Medical Corp., NIA Pty Ltd., CoDa Therapeutics, Inc., Cerylid Biosciences, Portland Orthopaedics, and Promics Pty Ltd. He is an Observer of Novasys Medical, Inc. He served as a Director of Victorian Workcover Authority from June 18, 2009 to June 17, 2015. He served as a Non Executive Director at Metalicity Limited. He served as a Director of Antipodean Pharmaceuticals, Inc., PLD Corporation Limited, Entigen corporation, and Phenomix Corporation. He served as a Non Executive Director of Sunshine Heart Inc from September 25, 2003 to May 21, 2015. He served as a Director of HealthCare Financial Partners, Inc. since January 1997. He served as a Non-Executive Director of CogState Limited from 1999 to October 2007 and Chemgenex Pharmaceuticals Ltd from February 2007 to June 2011. He has a license in clinical medicine from the Medical Board of Victoria, Australia and his Post-Graduate Studies were in anaesthesiology and intensive care. Dr. Brooke holds an M.B.A. from IMEDE (now IMD) in Lausanne, Switzerland and a Bachelor of Medicine and Surgery from the University of Melbourne in Australia.
Executive Profile
Column 1
Column 2
0
Simon GreenSenior Vice President of Product Development, Global Research & Development - CSL Behring and Australian Plasma Fractionation Operations, CSL Ltd.
Column 1
Column 2
Column 3
0
Age
Total Calculated Compensation
This person is connected to 0 Board Members in 0 different organizations across 2 different industries.
1
--
--
Background
Dr. Simon Green serves as Senior Vice President of Product Development, Global Research & Development - CSL Behring and Australian Plasma Fractionation Operations at CSL Ltd. Dr. Green served as General Manager of Marburg and Senior Vice President at CSL Behring LLC. Dr. Green was recruited to CSL Limited, CSL Behring's parent organization, in 1998. Dr. Green conducted scientific research at Genentech and Chiron Corporation in the San Francisco Bay area. Dr. Green led a collaborative project with the Ludwig Institute for Cancer Research on a novel melanoma vaccine, in Phase II clinical trials. He took on additional responsibilities leading CSL's project & portfolio management department and contributed to the management of its global R&D portfolio. Dr. Green served as head of Marburg R&D since 2004, and one year later assumed the additional responsibility of global head of R&D for ZLB Behring. Along with many of his colleagues, he is particularly pleased with obtaining regulatory approvals for Vivaglobin®, Sandoglobulin® liquid and volume-reduced Humate-P®/Haemate® P in major markets. He graduated as a biochemist from Monash University and completed his Ph.D. in Immunology at Melbourne (Australia) University.
ACR Price at posting:
75.0¢ Sentiment: Hold Disclosure: Held
